Binding Cell Receptors Key to New Prostate Cancer Diagnostic Test from NuView Life Sciences

A recent study validating urine diagnosis for cancer cell receptors in prostate cancer is eclipsing traditional methodology and warrants further steps toward FDA approval says cutting-edge biotechnology leader, NuView Life Sciences. CEO Paul Crowe will present the findings to the Boston Oncology Investor Conference, outlining the steps in the successful study and addressing the technology’s future.  …more…